Zoetis Inc. (ZTS Quick QuoteZTS - Free Report) emphasized market share protection, targeted pricing and innovation during its third-quarter 2026 earnings call, as companion animal demand remained pressured despite better-than-expected earnings and revenues.

Management highlighted improving promotional effectiveness, livestock resilience and disciplined spending while maintaining cautious expectations for 2027. Upcoming product launches remain central to its longer-term growth strategy.

ZTS Beats Zacks Estimates Despite Revenue Decline

Zoetis reported adjusted earnings of $1.75 per share, exceeding the Zacks Consensus Estimate of $1.51. Adjusted earnings increased 3% year over year on a reported basis.

Quarterly revenues of $2.39 billion surpassed the Zacks Consensus Estimate of $2.30 billion, representing a positive surprise of 3.90%, despite declining 1% year over year.

Zoetis Inc. Price, Consensus and EPS Surprise

Zoetis Inc. price-consensus-eps-surprise-chart | Zoetis Inc. Quote

Chief financial officer and chief operating officer James Saccaro attributed the revenue decline to a 1% pricing decrease and flat volumes. U.S. weakness contrasted with international growth, underscoring divergent regional demand trends.

Zoetis Narrows Revenue Outlook and Raises Earnings View

Zoetis narrowed its 2026 revenue guidance to $9.22-$9.32 billion, representing an organic operational decline of 1%-2%.

Management raised adjusted earnings guidance to $6.25-$6.35 per share and adjusted net income expectations to $2.60-$2.64 billion.

During the analyst discussion, Saccaro projected a high-single-digit sequential revenue decline in the fourth quarter, reflecting seasonality and promotional timing. He also emphasized conservative 2027 planning assumptions without expecting improvement in consumer spending or competition.

ZTS Promotions Slow Dermatology Market Share Losses

Global dermatology revenues declined 16% to $396 million, reflecting competitive pressure, pricing actions and weaker veterinary demand.

Chief executive officer Kristin Peck highlighted that targeted promotions reduced U.S. dermatology market share losses to four percentage points from seven points in the preceding quarter.

Responding to JPMorgan and Morgan Stanley analysts, Peck emphasized maintaining list prices while using targeted discounts to defend market share. She reiterated that restoring share stability remains the immediate objective before pursuing renewed gains.

Zoetis Sees Divergent Parasiticide and Pain Trends

The Simparica franchise generated $358 million in revenues, increasing 1%, supported by international expansion despite weaker U.S. demand.

During questions from Piper Sandler, Peck highlighted Simparica Trio's 22.5% U.S. market share and opportunities for further international penetration of triple-combination treatments.

Osteoarthritis pain revenues increased 2% to $137 million. International growth benefited from Lenivia and Portela launches, while U.S. performance remained pressured by lower veterinary visits and Librela safety perceptions.

ZTS Leans on Livestock and Diagnostics Growth

Livestock revenues increased 7% to $797 million, supported by cattle, swine and fish performance across markets.

Peck told a Stifel analyst that global protein demand continues supporting livestock growth, although disease outbreaks, weather conditions and production cycles remain sources of variability.

Companion animal diagnostics revenues increased 13% to $122 million. Saccaro attributed growth primarily to acquisitions, including VitalRADS and VPG, alongside continued adoption of diagnostic technologies.

Zoetis Prioritizes Cost Discipline and Product Innovation

Adjusted gross margin was 71%, declining 30 basis points year over year, reflecting pricing initiatives, product mix and inventory-related expenses.

During discussions with Morgan Stanley, Saccaro identified manufacturing efficiencies and SG&A savings as important priorities while maintaining investments in research and development.

Peck highlighted anticipated approvals for long-acting Cytopoint and Simparica Duo, alongside the approved Convenia RTU product. Management expects new launches to contribute more meaningfully beyond 2027.

ZTS Maintains Cautious Near-Term Expectations

Management's overall message balanced confidence in Zoetis' diversified portfolio with recognition of persistent affordability pressures and intense competition.

Peck emphasized defending established franchises while advancing innovation. Saccaro reinforced disciplined resource allocation and conservative assumptions as the company prepares for 2027.

Zoetis Zacks Rank and Style Scores Reflect Mixed Signals

Zoetis currently carries a Zacks Rank #3 (Hold), indicating a neutral near-term outlook under the earnings-estimate revision-based ranking system. Its Value Score of B and Momentum Score of B reflect relatively favorable valuation and price-momentum characteristics. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

However, its Growth Score of D signals weaker growth characteristics, while its VGM Score of C indicates a middle-range combined profile. The combination falls outside the preferred Zacks Rank #1 or #2 (Buy) with A- or B-rated Style Scores. The company's Zacks Rank may change as analysts revise earnings estimates following the quarterly results.